1 min read

Cleerly's AI scans comparable to gold-standard angiography

Only a few months after it emerged from stealth and burst onto the medtech scene, Cleerly is already living up to its name.

By Andrea Park

The newly published results of a study show that the New York City-based startup’s artificial intelligence-powered software does, indeed, allow healthcare providers to (ahem) clearly spot signs of heart disease without requiring the invasive evaluations that make up the current gold standard for coronary artery disease diagnosis.

In the latter method, the coronary angiogram, a catheter is threaded through the arm or leg to reach the heart, where it injects dye into its arteries so X-ray images can capture how blood flows through the vessels. Though serious complications from the procedure are rare, they potentially include injury to the catheterized artery, an allergic reaction or kidney damage from the dye, as well as heart attack, stroke and more. Read the full article HERE.

Cardiovascular Blind Spots and How Cleerly Is Changing the Game

Cardiovascular Blind Spots and How Cleerly Is Changing the Game

In The Future of Medicine Podcast, Aaron Wenzel, MD, and Jennifer Justus, MSN, APRN, FNP-C dive into how Cleerly has revolutionized their ability to...

Read More
AI Leading the Way to More Precise Diagnostics and Disease Risk Prediction

AI Leading the Way to More Precise Diagnostics and Disease Risk Prediction

Inside Precision Medicine features our Chief Scientific Officer, Dr. Udo Hoffmann, on how AI has changed CT imaging and the TRANSFORM trial that may...

Read More
Digital Health 50: The Most Promising Digital Health Companies of 2023

Digital Health 50: The Most Promising Digital Health Companies of 2023

Selected from more than 10,000 private healthcare companies, Cleerly is named one of CB Insight’s Digital Health 50 based on R&D, Mosaic scores,...

Read More
MedTech Strategist: Cleerly’s Personalized Approach to Heart Attack Risk

MedTech Strategist: Cleerly’s Personalized Approach to Heart Attack Risk

In this interview, Cleerly Founder and CEO, James Min, MD, shares how despite advances in cardiology, most heart attacks occur without warning....

Read More

Let’s Talk Medtech & CLEERLY

It’s American Heart Month, and Cleerly, a startup that uses artificial intelligence to change the way we diagnose cardiovascular disease is keeping...

Read More

Dicardiology: Cleerly Takes Precision Heart Care to the Next Level

Cleerly 2.2.0 includes UX updates and three high-value tools to better evaluate heart disease. Read on to see more from the article by Dicardiology. ...

Read More